89bio to Participate in the UBS Global Healthcare Conference

GlobeNewswire05:05

Madrigal, 89Bio Jump After Novo's Semaglutide Shows Promise in MASH

Yahoo Finance11/03 00:00

Suvretta Capital Management's Strategic Reduction in 89bio Inc Holdings

Yahoo Finance10/18 13:01

State Street Corp's Strategic Acquisition in 89bio Inc

Yahoo Finance10/18 01:05

89bio to Present New Analyses From ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting 2024

GlobeNewswire10/15 20:30

89bio Negotiates $50 Million Increase in Borrowing Capacity to $150 Million

MT Newswires10/04 01:33